Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#71 / 119 Total
DNA - Ginkgo Bioworks Holdings Inc - Stock Price Chart
TickerDNA [NYSE]
CompanyGinkgo Bioworks Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap1.57BEPS (ttm)-0.43
P/E-EPS this Y31.88%
Forward P/E-EPS next Y22.34%
PEG-EPS past 5Y-
P/S7.51EPS next 5Y19.50%
P/B1.47EPS Q/Q22.83%
Dividend-Sales Q/Q-52.98%
Insider Own32.59%Inst Own56.74%
Insider Trans-0.45%Inst Trans4.60%
Short Float20.87%EarningsMay 09/a
Analyst Recom3.43Target Price1.82
Avg Volume32.13M52W Range0.74 - 2.55
May-10-24Downgrade William Blair Mkt Perform → Underperform
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coen Steven P.See remarksMay 02 '24Sale0.84131,928111,479162,527May 06 04:53 PM
Dmytruk Mark E.See remarksMay 02 '24Sale0.8447,80640,396925,400May 06 04:55 PM
Dmytruk Mark E.See remarksApr 02 '24Sale1.0551,16953,727865,079Apr 04 04:40 PM
Dmytruk Mark E.See remarksMar 04 '24Sale1.2638,82648,765808,125Mar 06 05:08 PM
Dmytruk Mark E.See remarksFeb 02 '24Sale1.2139,56947,799761,737Feb 06 05:06 PM
CARM - Carisma Therapeutics Inc - Stock Price Chart
TickerCARM [NASD, RUT]
CompanyCarisma Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap61.48MEPS (ttm)-2.01
P/E-EPS this Y51.25%
Forward P/E-EPS next Y1.39%
PEG-EPS past 5Y24.98%
P/S4.08EPS next 5Y-
P/B5.64EPS Q/Q75.95%
Dividend-Sales Q/Q4.75%
Insider Own53.42%Inst Own17.29%
Insider Trans0.00%Inst Trans-32.33%
Short Float9.41%EarningsMay 09/b
Analyst Recom1.40Target Price7.60
Avg Volume168.75K52W Range1.47 - 9.77
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
CVRX - CVRx Inc - Stock Price Chart
TickerCVRX [NASD, RUT]
CompanyCVRx Inc
CountryUSA
IndustryMedical Devices
Market Cap157.03MEPS (ttm)-2.48
P/E-EPS this Y-30.65%
Forward P/E-EPS next Y25.51%
PEG-EPS past 5Y-27.17%
P/S3.73EPS next 5Y-
P/B2.37EPS Q/Q-90.12%
Dividend-Sales Q/Q34.98%
Insider Own55.51%Inst Own27.57%
Insider Trans-0.05%Inst Trans-5.10%
Short Float5.04%EarningsApr 30/a
Analyst Recom1.67Target Price16.60
Avg Volume192.53K52W Range7.25 - 33.13
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Palmer Craig E.SVP, U.S. SALESMar 25 '24Option Exercise0.249342211,229Mar 27 04:56 PM
JOHNSON & JOHNSON10% OwnerFeb 29 '24Option Exercise0.723,8552,7924,103,430Mar 06 03:42 PM
VERRASTRO PAULCHIEF MKTG & STRAT OFFICERFeb 20 '24Option Exercise5.145,00025,7055,000Feb 22 06:05 PM
VERRASTRO PAULCHIEF MKTG & STRAT OFFICERFeb 20 '24Sale21.912,54555,7482,455Feb 22 06:05 PM
JOHNSON & JOHNSON10% OwnerFeb 16 '24Sale25.813,72596,1424,099,575Mar 06 03:42 PM
NVRO - Nevro Corp - Stock Price Chart
TickerNVRO [NYSE, RUT]
CompanyNevro Corp
CountryUSA
IndustryMedical Devices
Market Cap359.59MEPS (ttm)-2.28
P/E-EPS this Y6.99%
Forward P/E-EPS next Y8.72%
PEG-EPS past 5Y-9.37%
P/S0.83EPS next 5Y-
P/B1.29EPS Q/Q29.22%
Dividend-Sales Q/Q5.78%
Insider Own4.87%Inst Own102.73%
Insider Trans0.00%Inst Trans-1.53%
Short Float11.08%EarningsMay 07/a
Analyst Recom3.28Target Price15.22
Avg Volume506.80K52W Range10.02 - 28.89
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCormick ShawnDirectorJun 07 '23Buy22.887,500171,63326,866Jun 09 04:37 PM
U - Unity Software Inc - Stock Price Chart
TickerU [NYSE]
CompanyUnity Software Inc
CountryUSA
IndustrySoftware - Application
Market Cap8.48BEPS (ttm)-2.24
P/E-EPS this Y-28.10%
Forward P/E20.68EPS next Y34.47%
PEG-EPS past 5Y-34.36%
P/S3.95EPS next 5Y-
P/B2.66EPS Q/Q-11.69%
Dividend-Sales Q/Q-7.99%
Insider Own28.20%Inst Own53.71%
Insider Trans-0.68%Inst Trans-0.34%
Short Float10.10%EarningsMay 09/a
Analyst Recom2.59Target Price27.97
Avg Volume8.92M52W Range22.20 - 50.08
Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carpenter Carol W.SVP & Chief Marketing OfficerMay 01 '24Sale24.182,00048,360442,617May 02 11:31 AM
Gupta AnirmaSVP, Chief Legal OfficerApr 29 '24Sale24.421,03725,324386,706Apr 30 01:18 PM
Carpenter Carol W.SVP & Chief Marketing OfficerApr 01 '24Sale26.582,00053,160444,617Apr 01 07:14 PM
Gupta AnirmaSVP, Chief Legal OfficerMar 25 '24Sale26.9392724,964387,743Mar 26 01:25 PM
The FelixSVP Product & Technology, GrowMar 08 '24Sale27.285,000136,400293,948Mar 08 06:55 PM
FLUX - Flux Power Holdings inc - Stock Price Chart
TickerFLUX [NASD]
CompanyFlux Power Holdings inc
CountryUSA
IndustryElectrical Equipment & Parts
Market Cap56.53MEPS (ttm)-0.43
P/E-EPS this Y6.67%
Forward P/E-EPS next Y61.22%
PEG-EPS past 5Y31.08%
P/S0.89EPS next 5Y-
P/B10.48EPS Q/Q-77.33%
Dividend-Sales Q/Q-4.18%
Insider Own27.33%Inst Own38.51%
Insider Trans-0.14%Inst Trans3.67%
Short Float1.46%EarningsMay 09/a
Analyst Recom1.00Target Price9.00
Avg Volume74.38K52W Range2.97 - 5.86
Flux Power Holdings, Inc. engages in the design, development, and sale of rechargeable lithium-ion energy storage systems for industrial applications. It focuses on electric forklifts and airport ground support equipment. The company was founded by Christopher L. Anthony and Michael Johnson on September 21, 1998 and is headquartered in Vista, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walters-Hoffert LisaDirectorApr 29 '24Sale4.505342,40327,050Apr 30 06:40 PM
Walters-Hoffert LisaDirectorApr 22 '24Sale4.035,90923,82926,058Apr 22 09:56 PM
DUTT RONALD FCEO and PresidentNov 02 '23Sale3.291,2214,02240,430Nov 06 06:52 PM
Scheiwe CharlesCFO and SecretaryNov 02 '23Sale3.296382,10214,028Nov 06 06:56 PM
Mason Jeffrey CurtisVice President of OperationsNov 02 '23Sale3.293891,2812,267Nov 06 06:54 PM
MEI - Methode Electronics, Inc. - Stock Price Chart
TickerMEI [NYSE, RUT]
CompanyMethode Electronics, Inc.
CountryUSA
IndustryElectronic Components
Market Cap384.69MEPS (ttm)-1.63
P/E-EPS this Y-138.93%
Forward P/E124.23EPS next Y110.70%
PEG-EPS past 5Y6.59%
P/S0.34EPS next 5Y15.00%
P/B0.46EPS Q/Q-160.34%
Dividend5.15%Sales Q/Q-7.35%
Insider Own6.59%Inst Own95.55%
Insider Trans0.00%Inst Trans-1.48%
Short Float6.69%EarningsMar 07/b
Analyst Recom3.00Target Price13.33
Avg Volume606.39K52W Range11.09 - 46.58
Methode Electronics, Inc. engages in the manufacture of component and subsystem devices. It operates through the following segments: Automotive, Interface, Industrial, and Medical. The Automotive segment supplies electronic and electromechanical devices, and related products to automobile original equipment manufacturers. The Interface segment provides a variety of copper and fiber-optic interface and interface solutions for the aerospace, appliance, commercial food service, construction, consumer, material handling, medical, military, mining, point-of-sale, and telecommunications markets. The Industrial segment manufactures external lighting solutions, industrial safety radio remote controls, braided flexible cables, current-carrying laminated busbars, and devices. The Medical segment refers to the medical device business. The company was founded by William Joseph McGinley in 1946 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUDA DONALD WChief Executive OfficerSep 21 '23Buy21.8023,245506,63623,245Sep 25 06:00 PM
ASPATORE WALTER JDirectorSep 20 '23Buy22.501,00022,50019,000Sep 22 06:00 PM
QLGN - Qualigen Therapeutics Inc - Stock Price Chart
TickerQLGN [NASD]
CompanyQualigen Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.93MEPS (ttm)-2.53
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y71.09%
P/S0.60EPS next 5Y-
P/B-EPS Q/Q69.23%
Dividend-Sales Q/Q-100.00%
Insider Own14.02%Inst Own2.42%
Insider Trans0.00%Inst Trans1.39%
Short Float0.74%Earnings-
Analyst Recom1.00Target Price33.50
Avg Volume75.40K52W Range0.27 - 1.26
Apr-16-24 07:00AM Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft (GlobeNewswire) -6.28%
Apr-10-24 08:00AM Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-09-24 08:00AM Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Nov-14-23 04:30PM Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 (GlobeNewswire)
Nov-07-23 08:30AM Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Oct-23-23 08:30AM Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire)
Sep-27-23 08:30AM Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 (GlobeNewswire)
Aug-30-23 07:09AM QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23 (Zacks)
Aug-17-23 08:30AM Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Aug-15-23 08:30AM Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire)
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.
DOMO - Domo Inc. - Stock Price Chart
TickerDOMO [NASD, RUT]
CompanyDomo Inc.
CountryUSA
IndustrySoftware - Application
Market Cap273.68MEPS (ttm)-2.10
P/E-EPS this Y-65.00%
Forward P/E-EPS next Y63.15%
PEG-EPS past 5Y25.98%
P/S0.86EPS next 5Y-
P/B-EPS Q/Q11.03%
Dividend-Sales Q/Q0.70%
Insider Own16.88%Inst Own63.34%
Insider Trans-3.24%Inst Trans0.68%
Short Float6.48%EarningsMar 07/a
Analyst Recom2.20Target Price14.50
Avg Volume416.10K52W Range7.24 - 18.19
Domo, Inc. designs, develops, and markets executive management software solutions. It offers customized software tools for business operations, customer relationship management, human resources, and financial reporting. The company was founded by Joshua G. James in September 2010 and is headquartered in American Fork, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jolley David RChief Financial OfficerApr 11 '24Sale8.5012,000102,000215,543Apr 12 04:40 PM
Thayne DarenCTO & EVP of ProductApr 04 '24Sale9.0422,500203,292343,758Apr 05 04:45 PM
Thayne DarenCTO & EVP of ProductMar 22 '24Sale9.592,86627,489365,958Mar 22 07:31 PM
James Joshua GFounder and CEOMar 21 '24Sale9.38107,0001,003,232881,765Mar 22 07:21 PM
Thayne DarenCTO & EVP of ProductMar 21 '24Sale9.3341,218384,605368,824Mar 22 07:31 PM
HEPA - Hepion Pharmaceuticals Inc - Stock Price Chart
TickerHEPA [NASD]
CompanyHepion Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap6.89MEPS (ttm)-12.32
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y63.67%
P/S-EPS next 5Y-
P/B1.09EPS Q/Q7.17%
Dividend-Sales Q/Q-
Insider Own1.42%Inst Own13.66%
Insider Trans6.88%Inst Trans-41.40%
Short Float1.19%Earnings-
Analyst Recom3.00Target Price22.00
Avg Volume72.61K52W Range1.22 - 20.66
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorNov 27 '23Buy3.052,5007,6259,501Nov 28 06:55 AM
Wijngaard PeterDirectorNov 24 '23Buy3.092,5007,7257,001Nov 28 06:55 AM
Wijngaard PeterDirectorSep 19 '23Buy5.641,0005,6404,501Sep 20 11:27 AM
Foster Robert TCEO and DirectorSep 18 '23Buy5.601,6008,96050,470Sep 19 09:01 AM
Wijngaard PeterDirectorSep 15 '23Buy5.602,00011,2013,501Sep 20 11:27 AM
13456789101112